The current issue of the Journal hosts an important Review Article authored by leaders in Hypertension research [1]. The title of the Review may leave the mind open to the hope that at least one of the available antihypertensive agents may be the ‘current best’ in the management of hypertensive patients affected by heart failure (HF) with preserved ejection fraction (HFpEF). Conversely, the reviews concludes that ‘all heart failure patients should be given all the drug classes mentioned above, if well tolerated’ [1].
